Real-Life Impact of Drug Toxicity on Dolutegravir Tolerability: Clinical Practice Data from a Multicenter Italian Cohort.
Adult
Anti-HIV Agents
/ therapeutic use
Cohort Studies
Drug Tolerance
Female
HIV Infections
/ drug therapy
HIV Integrase Inhibitors
/ toxicity
Heterocyclic Compounds, 3-Ring
/ therapeutic use
Humans
Italy
/ epidemiology
Male
Middle Aged
Oxazines
/ therapeutic use
Piperazines
/ therapeutic use
Pyridones
/ therapeutic use
HAART
HIV
dolutegravir
toxicity
Journal
Viruses
ISSN: 1999-4915
Titre abrégé: Viruses
Pays: Switzerland
ID NLM: 101509722
Informations de publication
Date de publication:
17 01 2022
17 01 2022
Historique:
received:
28
11
2021
revised:
08
01
2022
accepted:
11
01
2022
entrez:
22
1
2022
pubmed:
23
1
2022
medline:
17
2
2022
Statut:
epublish
Résumé
Dolutegravir (DTG) is currently one of the most used Integrase inhibitors (INI) in antiretroviral therapies (ARV) in both naïve and experienced people living with HIV (PLWHIV). We analyzed a multicenter cohort of PLWHIV, both naïve and experienced, starting an ARV including DTG. We enrolled 3775 PLWHIV: 2763 (73.2%) were males, with a median age of 50 years. During 9890.7 PYFU, we observed 930 discontinuations (9.4 per 100 PYFU). Estimated probabilities of maintaining DTG at three and five years were 75.1% and 67.2%, respectively. Treatment-naïve pts showed a lower probability of maintaining DTG at three and five years compared to treatment-experienced PLWHIV (log-rank
Identifiants
pubmed: 35062367
pii: v14010163
doi: 10.3390/v14010163
pmc: PMC8778073
pii:
doi:
Substances chimiques
Anti-HIV Agents
0
HIV Integrase Inhibitors
0
Heterocyclic Compounds, 3-Ring
0
Oxazines
0
Piperazines
0
Pyridones
0
dolutegravir
DKO1W9H7M1
Types de publication
Journal Article
Multicenter Study
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Références
J Int AIDS Soc. 2019 Jan;22(1):e25227
pubmed: 30663278
Clin Infect Dis. 2020 Nov 5;71(8):1920-1929
pubmed: 31905383
Eur J Hosp Pharm. 2020 Oct 13;:
pubmed: 33051194
Expert Rev Anti Infect Ther. 2020 Apr;18(4):279-292
pubmed: 32067525
Int J Antimicrob Agents. 2019 Dec;54(6):728-734
pubmed: 31521809
Lancet. 2013 Aug 24;382(9893):700-8
pubmed: 23830355
AIDS Rev. 2019;21(1):4-10
pubmed: 30899113
Clin Infect Dis. 2020 Oct 23;71(7):e200-e201
pubmed: 32198516
J Antimicrob Chemother. 2017 Jun 1;72(6):1752-1759
pubmed: 28333231
J Acquir Immune Defic Syndr. 2021 Nov 1;88(3):234-237
pubmed: 34446677
J Acquir Immune Defic Syndr. 2015 Dec 15;70(5):515-9
pubmed: 26262777
BMJ Open. 2019 Dec 2;9(12):e029960
pubmed: 31796476
Lancet. 2018 Mar 3;391(10123):839-849
pubmed: 29310899
HIV Med. 2017 Jan;18(1):56-63
pubmed: 27860104
AIDS. 2016 Nov 28;30(18):2831-2834
pubmed: 27824625